Natural Killer Cells Therapeutics Market by Therapeutics (NK Cell Therapies and NK Cell Directed Antibodies), Application (Cancer, Gastrointestinal Diseases, Immunoproliferative Disorders, and Others), and End User (Research Centers & Institutes, Hospitals, and Others): Global Opportunity Analysis and Industry Forecast, 2027
The Natural Killer (NK) Cells Therapeutics market refers to the pharmaceutical products and therapies aimed at utilizing and enhancing the functions of natural killer cells for therapeutic purposes. Natural killer cells are a type of immune cell that plays a crucial role in the body's innate immune response against infected or cancerous cells. Natural killer cells have demonstrated strong potential in cancer immunotherapy. They are capable of recognizing and eliminating tumor cells without prior sensitization, making them an attractive option for cancer treatment. The ability of NK cells to target a wide range of tumor types and their potential for combination therapy with other immune checkpoint inhibitors or monoclonal antibodies drive the demand for Natural Killer (NK) Cells Therapeutics. On the other hand, the higher costs incurred in the therapies and adverse side effects of natural killer cells therapeutics are key factors likely to restrict the market growth. Natural Killer Cells Therapeutics Market is likely to grow at a rate of 8.5% CAGR by 2027.
Natural Killer Cells Therapeutics Market by Therapeutics
Natural killer cell therapies
NK cell-directed antibodies
Natural Killer Cells Therapeuticsmarket by Application
Cancer
Gastrointestinal diseases
Immunoproliferative disorders
Natural Killer Cells Therapeuticsmarket by End User
Research centers and institutes
Hospitals and clinics
Natural Killer Cells Therapeutics Market by Geography
North America
Europe
Asia Pacific
Rest of the World
Natural Killer cell-based therapies are being investigated and developed for various medical conditions, including:
Cancer Immunotherapy: Natural Killer cells have the ability to recognize and eliminate cancer cells. NK cell-based immunotherapies, such as adoptive cell therapy (ACT) and chimeric antigen receptor (CAR) Natural Killer cell therapy, are being developed to enhance the anti-tumor activity of Natural Killer cells. These therapies involve isolating and expanding NK cells from a donor or the patient's own cells, modifying them to improve their targeting capabilities, and then reinfusing them into the patient to target and kill cancer cells.
Infectious Diseases: NK cells also play a role in the defense against viral infections, such as hepatitis B and C, HIV, and cytomegalovirus (CMV). Therapeutic approaches that aim to enhance NK cell function or stimulate their antiviral activity are being explored for the treatment of these infections.
Autoimmune Disorders: In certain autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), the balance between Natural Killer cell activation and regulation is disrupted. Strategies to modulate Natural Killer cell activity and restore immune balance are being investigated as potential therapeutic options for these conditions.
The NK cells therapeutics market is driven by the increasing understanding of the role of NK cells in immune responses and the growing interest in harnessing their therapeutic potential. Pharmaceutical companies and biotechnology firms are actively involved in research and development efforts to optimize natural killer cells isolation, expansion, and manipulation techniques.
The major leading companies of the natural killer cells therapeutics market are Affimed N.V., Celgene Corporation, Fate Therapeutics Inc., Fortress Biotech, Glycostem Therapeutics Bv, Nkarta Therapeutics, Inc., Nkt Therapeutics Inc., Innate Pharma Sa, Nantkwest Inc, and Ziopharm Oncology Inc.
The market also includes healthcare providers, hospitals, and specialized treatment centers that administer NK cell-based therapies. Diagnostic laboratories may be involved in assessing patients' immune profiles and identifying suitable candidates for NK cell therapies.
As research progresses and clinical trials continue, the market is expected to witness advancements in manufacturing processes, cell engineering techniques, and the development of combination therapies. Challenges such as the optimization of NK cell expansion and persistence, reducing potential side effects, and ensuring long-term therapeutic efficacy are areas of active investigation in the field of natural killer cells therapeutics.
It's important to note that the Natural Killer Cells Therapeutics market is still evolving, and regulatory approvals for specific Natural Killer cell-based therapies may vary by region.
This report depicts the accurate evaluation of the acoustic insulation market size and its share in the parent market
Exact estimations of forthcoming trends and changes in market dynamics are also included in this report
This report provides the growth of the acoustic insulation market industry across North America, Asia Pacific, Europe, rest of the world.
Comprehensive analysis of the market's competitive outlook and detailed information of vendors is depicted in the study.
Exclusive details of factors which will challenge the growth of Natural Killer Cells Therapeutics market players.
Natural Killer Cells Therapeutics Market by Therapeutics
Natural killer cell therapies
NK cell-directed antibodies
Natural Killer Cells Therapeuticsmarket by Application
Cancer
Gastrointestinal diseases
Immunoproliferative disorders
Natural Killer Cells Therapeuticsmarket by End User
Research centers and institutes
Hospitals and clinics
Natural Killer Cells Therapeutics Market by Geography
North America
Europe
Asia Pacific
Rest of the World
Natural Killer cell-based therapies are being investigated and developed for various medical conditions, including:
Cancer Immunotherapy: Natural Killer cells have the ability to recognize and eliminate cancer cells. NK cell-based immunotherapies, such as adoptive cell therapy (ACT) and chimeric antigen receptor (CAR) Natural Killer cell therapy, are being developed to enhance the anti-tumor activity of Natural Killer cells. These therapies involve isolating and expanding NK cells from a donor or the patient's own cells, modifying them to improve their targeting capabilities, and then reinfusing them into the patient to target and kill cancer cells.
Infectious Diseases: NK cells also play a role in the defense against viral infections, such as hepatitis B and C, HIV, and cytomegalovirus (CMV). Therapeutic approaches that aim to enhance NK cell function or stimulate their antiviral activity are being explored for the treatment of these infections.
Autoimmune Disorders: In certain autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), the balance between Natural Killer cell activation and regulation is disrupted. Strategies to modulate Natural Killer cell activity and restore immune balance are being investigated as potential therapeutic options for these conditions.
The NK cells therapeutics market is driven by the increasing understanding of the role of NK cells in immune responses and the growing interest in harnessing their therapeutic potential. Pharmaceutical companies and biotechnology firms are actively involved in research and development efforts to optimize natural killer cells isolation, expansion, and manipulation techniques.
The major leading companies of the natural killer cells therapeutics market are Affimed N.V., Celgene Corporation, Fate Therapeutics Inc., Fortress Biotech, Glycostem Therapeutics Bv, Nkarta Therapeutics, Inc., Nkt Therapeutics Inc., Innate Pharma Sa, Nantkwest Inc, and Ziopharm Oncology Inc.
The market also includes healthcare providers, hospitals, and specialized treatment centers that administer NK cell-based therapies. Diagnostic laboratories may be involved in assessing patients' immune profiles and identifying suitable candidates for NK cell therapies.
As research progresses and clinical trials continue, the market is expected to witness advancements in manufacturing processes, cell engineering techniques, and the development of combination therapies. Challenges such as the optimization of NK cell expansion and persistence, reducing potential side effects, and ensuring long-term therapeutic efficacy are areas of active investigation in the field of natural killer cells therapeutics.
It's important to note that the Natural Killer Cells Therapeutics market is still evolving, and regulatory approvals for specific Natural Killer cell-based therapies may vary by region.
This report depicts the accurate evaluation of the acoustic insulation market size and its share in the parent market
Exact estimations of forthcoming trends and changes in market dynamics are also included in this report
This report provides the growth of the acoustic insulation market industry across North America, Asia Pacific, Europe, rest of the world.
Comprehensive analysis of the market's competitive outlook and detailed information of vendors is depicted in the study.
Exclusive details of factors which will challenge the growth of Natural Killer Cells Therapeutics market players.
1. EXECUTIVE SUMMARY
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. THERAPEUTICS: MARKET SIZE & ANALYSIS
5.1. NK Cell Therapies
5.2. NK Cell Directed Antibodies
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Cancer
6.2. Gastrointestinal Diseases
6.3. Immunoproliferative Disorders
7. END USER: MARKET SIZE & ANALYSIS
7.1. Research Centers& Institutes
7.2. Hospitals
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. NKARTA THERAPEUTICS, INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ZIOPHARM ONCOLOGY INC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. GLYCOSTEM THERAPEUTICS BV
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. FATE THERAPEUTICS INC.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. FORTRESS BIOTECH
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. NANTKWEST INC.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. INNATE PHARMA SA.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. NKT THERAPEUTICS INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. CELGENE CORPORATION
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. AFFIMED N.V
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
2. INDUSTRY OUTLOOK
2.1. Industry Overview
2.2. Industry Trends
3. MARKET SNAPSHOT
3.1. Market Definition
3.2. Market Outlook
3.2.1. Porter Five Forces
3.3. Related Markets
4. MARKET CHARACTERISTICS
4.1. Market Overview
4.2. Market Segmentation
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. DRO - Impact Analysis
5. THERAPEUTICS: MARKET SIZE & ANALYSIS
5.1. NK Cell Therapies
5.2. NK Cell Directed Antibodies
6. APPLICATION: MARKET SIZE & ANALYSIS
6.1. Cancer
6.2. Gastrointestinal Diseases
6.3. Immunoproliferative Disorders
7. END USER: MARKET SIZE & ANALYSIS
7.1. Research Centers& Institutes
7.2. Hospitals
8. GEOGRAPHY: MARKET SIZE & ANALYSIS
8.1. Overview
8.2. North America
8.3. Europe
8.4. Asia Pacific
8.5. Rest of the World
9. COMPETITIVE LANDSCAPE
9.1. Competitor Comparison Analysis
9.2. Market Developments
9.2.1. Mergers and Acquisitions, Legal, Awards, Partnerships
9.2.2. Product Launches and execution
10. VENDOR PROFILES
10.1. NKARTA THERAPEUTICS, INC.
10.1.1. Overview
10.1.2. Financial Overview
10.1.3. Product Offerings
10.1.4. Developments
10.1.5. Business Strategy
10.2. ZIOPHARM ONCOLOGY INC
10.2.1. Overview
10.2.2. Financial Overview
10.2.3. Product Offerings
10.2.4. Developments
10.2.5. Business Strategy
10.3. GLYCOSTEM THERAPEUTICS BV
10.3.1. Overview
10.3.2. Financial Overview
10.3.3. Product Offerings
10.3.4. Developments
10.3.5. Business Strategy
10.4. FATE THERAPEUTICS INC.
10.4.1. Overview
10.4.2. Financial Overview
10.4.3. Product Offerings
10.4.4. Developments
10.4.5. Business Strategy
10.5. FORTRESS BIOTECH
10.5.1. Overview
10.5.2. Financial Overview
10.5.3. Product Offerings
10.5.4. Developments
10.5.5. Business Strategy
10.6. NANTKWEST INC.
10.6.1. Overview
10.6.2. Financial Overview
10.6.3. Product Offerings
10.6.4. Developments
10.6.5. Business Strategy
10.7. INNATE PHARMA SA.
10.7.1. Overview
10.7.2. Financial Overview
10.7.3. Product Offerings
10.7.4. Developments
10.7.5. Business Strategy
10.8. NKT THERAPEUTICS INC
10.8.1. Overview
10.8.2. Financial Overview
10.8.3. Product Offerings
10.8.4. Developments
10.8.5. Business Strategy
10.9. CELGENE CORPORATION
10.9.1. Overview
10.9.2. Financial Overview
10.9.3. Product Offerings
10.9.4. Developments
10.9.5. Business Strategy
10.10. AFFIMED N.V
10.10.1. Overview
10.10.2. Financial Overview
10.10.3. Product Offerings
10.10.4. Developments
10.10.5. Business Strategy
11. ANALYST OPINION
12. ANNEXURE
12.1. Report Scope
12.2. Market Definitions
12.3. Research Methodology
12.3.1. Data Collation and In-house Estimation
12.3.2. Market Triangulation
12.3.3. Forecasting
12.4. Report Assumptions
12.5. Declarations
12.6. Stakeholders
12.7. Abbreviations
LIST OF TABLES
TABLE 1. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR NATURAL KILLER CELL THERAPIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR NK CELL-DIRECTED ANTIBODIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR GASTROINTESTINAL DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR IMMUNOPROLIFERATIVE DISORDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR RESEARCH CENTERS AND INSTITUTES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR HOSPITALS AND CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR DEEP VEIN THROMBOSIS (DVT), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR PULMONARY EMBOLISM (PE), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 17. U.SNATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 18. U.SNATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 19. U.SNATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 20. CANADANATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 21. CANADANATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 22. CANADANATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 23. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 25. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, END USER,2021-2027 (USD BILLION)
TABLE 27. GERMANY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 28. GERMANY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 30. U.K NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 31. U.K NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 32. U.K NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 33. FRANCE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS2021-2027 (USD BILLION)
TABLE 34. FRANCE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 36. ITALY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 37. ITALY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 39. SPAIN NATURAL KILLER CELLS THERAPEUTICS MARKETVALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 40. SPAIN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 42. ROE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 43. ROE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 44. ROE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 49. CHINA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 50. CHINA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 52. INDIA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 53. INDIA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 55. JAPAN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 56. JAPAN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 64. NKARTA THERAPEUTICS, INC: FINANCIALS
TABLE 65. NKARTA THERAPEUTICS, INC: PRODUCTS & SERVICES
TABLE 66. NKARTA THERAPEUTICS, INC: RECENT DEVELOPMENTS
TABLE 67. ZIOPHARM ONCOLOGY INC.: FINANCIALS
TABLE 68. ZIOPHARM ONCOLOGY INC: PRODUCTS & SERVICES
TABLE 69. ZIOPHARM ONCOLOGY INC: RECENT DEVELOPMENTS
TABLE 70. GLYCOSTEM THERAPEUTICS BV: FINANCIALS
TABLE 71. GLYCOSTEM THERAPEUTICS BV: PRODUCTS & SERVICES
TABLE 72. GLYCOSTEM THERAPEUTICS BV: RECENT DEVELOPMENTS
TABLE 73. FATE THERAPEUTICS INC: FINANCIALS
TABLE 74. FATE THERAPEUTICS INC: PRODUCTS & SERVICES
TABLE 75. FATE THERAPEUTICS INC: RECENT DEVELOPMENTS
TABLE 76. FORTRESS BIOTECH: FINANCIALS
TABLE 77. FORTRESS BIOTECH: PRODUCTS & SERVICES
TABLE 78. FORTRESS BIOTECH: RECENT DEVELOPMENTS
TABLE 79. NANTKWEST INC.: FINANCIALS
TABLE 80. NANTKWEST INC: PRODUCTS & SERVICES
TABLE 81. NANTKWEST INC: RECENT DEVELOPMENTS
TABLE 82. INNATE PHARMA SA: FINANCIALS
TABLE 83. INNATE PHARMA SA: PRODUCTS & SERVICES
TABLE 84. INNATE PHARMA SA: RECENT DEVELOPMENTS
TABLE 85. NKT THERAPEUTICS INC: FINANCIALS
TABLE 86. NKT THERAPEUTICS INC: PRODUCTS & SERVICES
TABLE 87. NKT THERAPEUTICS INC: RECENT DEVELOPMENTS
TABLE 88. CELGENE CORPORATION: FINANCIALS
TABLE 89. CELGENE CORPORATION: PRODUCTS & SERVICES
TABLE 90. CELGENE CORPORATION: RECENT DEVELOPMENTS
TABLE 91. AFFIMED N.V.: FINANCIALS
TABLE 92. AFFIMED N.V.: PRODUCTS & SERVICES
TABLE 93. AFFIMED N.V.: RECENT DEVELOPMENTS
TABLE 1. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 2. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR NATURAL KILLER CELL THERAPIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 3. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR NK CELL-DIRECTED ANTIBODIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 4. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 5. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR CANCER, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 6. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR GASTROINTESTINAL DISEASES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 7. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR IMMUNOPROLIFERATIVE DISORDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 8. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 9. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR RESEARCH CENTERS AND INSTITUTES, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 10. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR HOSPITALS AND CLINICS, BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 11. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR DEEP VEIN THROMBOSIS (DVT), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 12. GLOBAL NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE FOR PULMONARY EMBOLISM (PE), BY GEOGRAPHY, 2021-2027 (USD BILLION)
TABLE 13. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 14. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 15. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 16. NORTH AMERICA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 17. U.SNATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 18. U.SNATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 19. U.SNATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 20. CANADANATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 21. CANADANATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 22. CANADANATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 23. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 24. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 25. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 26. EUROPENATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, END USER,2021-2027 (USD BILLION)
TABLE 27. GERMANY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 28. GERMANY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 29. GERMANY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 30. U.K NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 31. U.K NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 32. U.K NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 33. FRANCE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS2021-2027 (USD BILLION)
TABLE 34. FRANCE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 35. FRANCE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 36. ITALY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 37. ITALY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 38. ITALY NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 39. SPAIN NATURAL KILLER CELLS THERAPEUTICS MARKETVALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 40. SPAIN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 41. SPAIN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 42. ROE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 43. ROE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 44. ROE NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 45. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)
TABLE 46. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 47. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 48. ASIA PACIFC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 49. CHINA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 50. CHINA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 51. CHINA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 52. INDIA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 53. INDIA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 54. INDIA NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 55. JAPAN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 56. JAPAN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 57. JAPAN NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 58. REST OF APAC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 59. REST OF APAC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 60. REST OF APAC NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 61. REST OF WORLD NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY THERAPEUTICS, 2021-2027 (USD BILLION)
TABLE 62. REST OF WORLD NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY APPLICATION, 2021-2027 (USD BILLION)
TABLE 63. REST OF WORLD NATURAL KILLER CELLS THERAPEUTICS MARKET VALUE, BY END USER, 2021-2027 (USD BILLION)
TABLE 64. NKARTA THERAPEUTICS, INC: FINANCIALS
TABLE 65. NKARTA THERAPEUTICS, INC: PRODUCTS & SERVICES
TABLE 66. NKARTA THERAPEUTICS, INC: RECENT DEVELOPMENTS
TABLE 67. ZIOPHARM ONCOLOGY INC.: FINANCIALS
TABLE 68. ZIOPHARM ONCOLOGY INC: PRODUCTS & SERVICES
TABLE 69. ZIOPHARM ONCOLOGY INC: RECENT DEVELOPMENTS
TABLE 70. GLYCOSTEM THERAPEUTICS BV: FINANCIALS
TABLE 71. GLYCOSTEM THERAPEUTICS BV: PRODUCTS & SERVICES
TABLE 72. GLYCOSTEM THERAPEUTICS BV: RECENT DEVELOPMENTS
TABLE 73. FATE THERAPEUTICS INC: FINANCIALS
TABLE 74. FATE THERAPEUTICS INC: PRODUCTS & SERVICES
TABLE 75. FATE THERAPEUTICS INC: RECENT DEVELOPMENTS
TABLE 76. FORTRESS BIOTECH: FINANCIALS
TABLE 77. FORTRESS BIOTECH: PRODUCTS & SERVICES
TABLE 78. FORTRESS BIOTECH: RECENT DEVELOPMENTS
TABLE 79. NANTKWEST INC.: FINANCIALS
TABLE 80. NANTKWEST INC: PRODUCTS & SERVICES
TABLE 81. NANTKWEST INC: RECENT DEVELOPMENTS
TABLE 82. INNATE PHARMA SA: FINANCIALS
TABLE 83. INNATE PHARMA SA: PRODUCTS & SERVICES
TABLE 84. INNATE PHARMA SA: RECENT DEVELOPMENTS
TABLE 85. NKT THERAPEUTICS INC: FINANCIALS
TABLE 86. NKT THERAPEUTICS INC: PRODUCTS & SERVICES
TABLE 87. NKT THERAPEUTICS INC: RECENT DEVELOPMENTS
TABLE 88. CELGENE CORPORATION: FINANCIALS
TABLE 89. CELGENE CORPORATION: PRODUCTS & SERVICES
TABLE 90. CELGENE CORPORATION: RECENT DEVELOPMENTS
TABLE 91. AFFIMED N.V.: FINANCIALS
TABLE 92. AFFIMED N.V.: PRODUCTS & SERVICES
TABLE 93. AFFIMED N.V.: RECENT DEVELOPMENTS
